NCT00193089View on ClinicalTrials.gov

Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

April 30, 2005

Study Completion Date

September 30, 2009

Conditions
Breast Cancer
Interventions
DRUG

Docetaxel

Docetaxel

DRUG

Vinorelbine

Vinorelbine

DRUG

Trastuzumab

Trastuzumab

Sponsors
All Listed Sponsors
collaborator

Aventis Pharmaceuticals

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER